non-squamous non-small cell lung cancer
Conditions
Interventions
Pemetrexed and Bevacizumab administered every 3 week until observation of progression or intolerable toxicity.
Sponsors
Niigata Lung Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) StageIIIB/IV or postoperative recurrence Non-small cell lung cancer and Non-Squamous cell carcinoma proven by histology and/or cytology 2) EGFR mutation or ALK rearrangement status is not required 3) No prior chemotherapy 4) 20 years or older and PS 2 5) At least one or more measurable lesion by RECIST ver1.1 6) Adequate organ function 7) Interval -Palliative radiotherapy >4wks -Surgery >4wks -thoracic drainage>1wks -biopsy with dissection, indwelling port >1wks -blood transfusion >2wks 8) Life expectancy more than three months. 9) Written Informed Consent
Exclusion criteria
Exclusion criteria: 1) History of hemoptysis 2) High risk of bleeding or thrombus events 3) History of anticoagulant within 10 days before enrollment 4) Active radiation pneumonitis or esophagitis 5) Uncontrollable hypertension 6) Symptomatic brain metastasis 7) Scheduled operation 8) Severe complications 9) Problematic infection 10) History of active double cancer 11) No intention to birth control 12) Unstable psychic disorder 13) History of treatment drug 14) Decision of ineligibility by a physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| RR,DCR,OS,TTF,QOL,safety | — |
Countries
Japan
Contacts
Public ContactHirohisa Yoshizawa
Niigata University Medical and Dental Hospital Bioscience Medical Research Center
Outcome results
None listed